Neurogene Inc.
HealthcareNASDAQ:NGNE · NASDAQ Global Market
+$0.10 today
Vol 0.11M · Avg 0.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$98.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.03, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 -100.0% | $925.0K | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.2M -1.7% | $3.2M -0.5% | $3.3M +2.1% | $3.2M -92.4% | $42.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$3.2M -37.5% | -$2.3M +28.8% | -$3.3M -2.1% | -$3.2M +92.4% | -$42.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | -251.0% | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $75.0M +23.1% | $60.9M +37.2% | $44.4M -6.5% | $47.5M +12.4% | $42.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $25.1M +11.1% | $22.6M +102.1% | $11.2M +24.2% | $9.0M +9.0% | $8.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $100.0M +24.6% | $80.3M +53.4% | $52.3M -1.9% | $53.3M +544.8% | $8.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $3.2M -1.5% | $3.3M +3.2% | $3.2M +237.5% | $947.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$90.3M -25.7% | -$71.9M -117.8% | -$33.0M +36.5% | -$52.0M -4.9% | -$49.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | -7771.4% | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$103.2M -24.9% | -$82.6M -48.6% | -$55.6M +1.7% | -$56.5M -11.8% | -$50.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | -8930.3% | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.5M +36.4% | $8.5M +186.9% | $3.0M +120.7% | $1.3M +6936.8% | $19.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.0K -58.3% | $12.0K +0.0% | $12.0K +500.0% | $2.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.9M +72.3% | $7.5M -61.3% | $19.3M +1350.8% | $1.3M +7711.8% | $17.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$90.4M -20.2% | -$75.1M -106.9% | -$36.3M +34.2% | -$55.2M -9.2% | -$50.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | -8123.7% | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$90.4M -20.2% | -$75.1M -106.9% | -$36.3M +34.2% | -$55.2M -9.2% | -$50.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | -8123.7% | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 +0.9% | -$4 -51.2% | -$3 +34.2% | -$4 -367.4% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 +0.9% | -$4 -51.2% | -$3 +34.2% | -$4 -367.4% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $21.2M +20.5% | $17.6M +37.0% | $12.8M +0.0% | $12.8M -76.7% | $55.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $21.2M +20.5% | $17.6M +37.0% | $12.8M +0.0% | $12.8M -76.7% | $55.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.98B
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
Benitec Biopharma Inc.
NASDAQ:BNTC
$293.44M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NGNE generate?
Neurogene Inc. (NGNE) reported $0.00 of revenue in fiscal 2025.
Is NGNE profitable?
Neurogene Inc. (NGNE) reported -$90,351,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.